Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 2 of the last 3 fiscal years.
-
Tight liquidity NBB
Cash and receivables cover 11 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
AMPHIKTION from Brussel, company number BE0803632924, closed financial year 2025 with a result of € -69,239 after tax. For that financial year AMPHIKTION recorded a gross margin of € 96,222 and equity of € -153,074. Compared with financial year 2024, the result moved from € 33,500 to € -69,239. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on October 31, 2026.
€ -153,074
▲ € 43,184 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -69,239
▼ still € 33,500 profit in 2024
Profit after tax over the fiscal year.
€ 5
▼ € 3,636 vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -305,497.
People and assets in 2025
€ 125
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 3,091
▼ 21% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 1.4 million
▼ 6% vs 2024
€ 95,761 is repaid this year. At this pace the long-term loan is gone in ≈ 15 years.
€ 16,935
▲ 21% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 5,216
▼ 7% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|
| Gross margin | € 8,081 | € 200,476 | € 96,222 | ▼ 52% |
| Profit after taxes | € -269,758 | € 33,500 | € -69,239 | ▼ € 102,739 |
| Equity | € 170,242 | € -196,258 | € -153,074 | ▲ € 43,184 |
| Total debts | € 1,681,058 | € 1,760,332 | € 1,884,316 | ▲ 7% |
| Cash | € 5,516 | € 3,641 | € 5 | ▼ € 3,636 |
| Land & buildings | € 1,837,319 | € 1,506,480 | € 1,675,000 | ▲ 11% |
| Retained profit | € -269,758 | € -236,258 | € -305,497 | ▼ € 69,239 |
| Bank debt | € 1,485,419 | € 1,484,907 | € 1,392,628 | ▼ 6% |
| Balance sheet total | € 1,851,300 | € 1,564,074 | € 1,731,242 | ▲ 11% |
By gross margin, AMPHIKTION ranks 44th of 138 companies with main activity “Activiteiten van holdings” in Brussel that publish figures (fiscal year 2025).
Key figures of AMPHIKTION, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about AMPHIKTION the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to AMPHIKTION?
What happened at AMPHIKTION in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 69,239 (▼ € 102,739 vs 2024). filed late Source: NBB ↗
- Capital increase of € 16, published in the Gazette. Source: Staatsblad ↗
- Incorporation, published in the Gazette. Source: Staatsblad ↗
- New establishment in Brussel. KBO
- PHARMALEGAL BV became a director. NBB
In short
From € 269,758 loss in 2023 to € 69,239 loss in 2025.
Best year ever: 2024, with € 33,500 profit.
Management
Behind AMPHIKTION is PHARMALEGAL BV. PHARMALEGAL BV is also behind ZORGPUNT, Lynxcare Clinical Informatics, ASYLIA DIAGNOSTICS, Curaevia and Thuiszorg Cooperatie.
Directors
According to the 2025 annual accounts
Director · represented by DE FEU Georges
Also active at: ZORGPUNT, Lynxcare Clinical Informatics, ASYLIA DIAGNOSTICS, Curaevia, Thuiszorg Cooperatie, PharmaBXL
since 2023
Establishments
Establishment units
Physical locations of this company
Zavelput 17
1000 Brussel
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.
All companies at this address →Association d'Entraide homophile - Association pour la Défense des Homophiles
PHARMACIE BOTANIQUE
€ 236,541 gross margin · 2023
PharmaBXL same network
€ 436,169 gross margin · 2024
PharmaPROP.BXL
€ 50,325 gross margin · 2024
PharmaOPS.BXL
€ 596,330 gross margin · 2024
+1 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in Brussel
Same main activity (Activiteiten van holdings), 259 active companies in Brussel, largest first.
€ 933.7 million revenue · 2025
Société belge des Combustibles nucléaires Synatom
€ 299.8 million revenue · 2025
€ 139.5 million revenue · 2025
€ 61.3 million revenue · 2025
€ 34.6 million revenue · 2025
€ 31 million revenue · 2025
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Incorporation
Source: Deed ↗- LEBA(oprichter) 90.9%
- PharmaLegal(oprichter) 6.8%
- DE FEU Georges Charlotte Jan Madelaine(oprichter) 2.3%
Details
- Company number
- 0803.632.924
- VAT number
- BE 0803.632.924
- Registered office
- Zavelput 17, 1000 Brussel
- Names & denominations
- AMPHIKTION
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 5 July 2023
- Peppol
- Active · Active since 25 Sept 2026
- Activities · NACE
Activiteiten van holdings
Holdings
Handel in eigen onroerend goed